RxSight (RXST) Net Equity Issued and Repurchased (2022 - 2026)

RxSight's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $144000.0 for Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 79.31% year-over-year to $144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 70.08% YoY) and the FY2025 annual result came in at $4.0 million, down 81.02% from the prior year.
• Net Equity Issued and Repurchased was $144000.0 for Q1 2026 at RxSight, down from $1.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $11.7 million in Q3 2023 and bottomed at $131000.0 in Q3 2025.
• A 5-year average of $3.0 million and a median of $2.1 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased jumped 7968.97% — and 2025, when it slumped 96.58%.
• RxSight's Net Equity Issued and Repurchased stood at $589000.0 in 2022, then surged by 508.32% to $3.6 million in 2023, then decreased by 16.61% to $3.0 million in 2024, then slumped by 64.66% to $1.1 million in 2025, then tumbled by 86.36% to $144000.0 in 2026.
• Business Quant data shows RXST's Net Equity Issued and Repurchased at $144000.0 in Q1 2026, $1.1 million in Q4 2025, and $131000.0 in Q3 2025.